Emergent BioSolutions Inc. (EBS)
EBS trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/0001367644-26-000015-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | EBS on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2006 |
| SEC CIK | 0001367644 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $742.9M |
| Net income | $52.6M |
| Operating income | $100.1M |
| Net margin | 7.1% |
| Operating margin | 13.5% |
| Revenue growth | -28.8% |
| Cash | $205.4M |
| Total assets | $1.3B |
| P/E (computed) | 5.7× |
| P/S (computed) | 0.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $175.7M cash; operating cash flow $50.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 51,415,182 (2026-10-26); 52,519,964 a year earlier; 51,884,398 three years earlier. | Cover page 2026-10-26 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Tysons, Virginia, United States | PCAOB Form AP 2026-03-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $110.0M | -$32.7M | $100.1M | $175.7M | $514.3M | $649.1M | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $234.3M | -$180.2M | $56.1M | $139.7M | $589.7M | $770.2M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $156.1M | $6.8M | -$33.8M | $160.3M | $589.7M | $676.8M | 10-Q 2026-05-01 |
| Q4 2025 2025-12-31 | $148.7M | -$54.6M | $77.7M | $205.4M | $589.7M | $742.9M | 10-K 2026-02-27 |
| Q3 2025 2025-09-30 | $231.1M | $51.2M | -$2.3M | $245.5M | $693.1M | $788.9M | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $140.9M | -$12.0M | $106.4M | $267.3M | $700.0M | $851.6M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $222.2M | $68.0M | -$11.2M | $149.1M | $700.0M | $965.4M | 10-Q 2026-05-01 |
| Q4 2024 2024-12-31 | $194.7M | -$31.3M | -$79.9M | $99.5M | $700.0M | $1.0B | 10-K 2026-02-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-08-07 |
| Latest annual report | 10-K | 2026-02-27 |
| Latest quarterly / interim 10-Q 9.30.26 | 10-Q | 2026-11-03 |
| Latest current report 8-K PR 11.4.2026 | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.5% |
| 1 month | -16.2% |
| 3 months | +29.0% |
| Year to date | -53.2% |
| 1 year | -43.9% |
| From 52-week high | -58.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ALT | Altimmune Inc. | $1.56 | -5.17% | $303.6M |
| EVMN | Evommune Inc. | $7.10 | -6.95% | $293.6M |
| GALT | Galectin Therapeutics Inc. | $3.02 | -0.98% | $305.2M |
| BNTC | Benitec Biopharma Inc. | $8.54 | -5.53% | $308.5M |
| ENTA | Enanta Pharmaceuticals Inc. | $10.67 | -2.91% | $310.8M |
| LRMR | Larimar Therapeutics Inc. | $3.00 | -0.66% | $311.6M |
| FULC | Fulcrum Therapeutics Inc. | $3.71 | -1.59% | $283.4M |
| PRLD | Prelude Therapeutics Incorporated | $3.41 | -1.16% | $272.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier